1 Additional studies should evaluate FujiLAM in clinical practice settings
2 Additional studies should evaluate unplanned return to OR as a measure o
3 environmentally relevant levels of DE-71, additional
animal studies should be conducted that further characterize PBDE-in
4 Clinical studies should reveal if treatment with LP results in improve
5 Further well-designed
clinical studies should evaluate the optimal intakes of DHA and AA in
6 s between squid and white sharks, in which future
ecosystem studies should consider both species for management and conse
7 Further studies should be conducted to determine the probability of o
8 Further studies should focus on reducing mosaicism when using CRISPR/
9 We suggest that
further studies should focus on the dynamics of the relationship betw
10 and freezing tolerances of plants, concluding that
further studies should routinely incorporate symbiotic microbes in th
11 Therefore,
further studies should focus on association with altered taste prefer
12 Future studies should address surveillance and management after newl
13 Future studies should apply the rOMT analysis approach to confirm GS
14 Future studies should assess participants' skills, attitudes, satisf
15 Future studies should be designed to determine if our findings direc
16 Future studies should clarify the specific mechanisms through which
17 Future studies should consider MSM status in gut microbiome analyses
18 Future studies should emphasize collection of relevant psychosocial
19 Future studies should evaluate long-term outcomes of oral health as
20 Future studies should evaluate other mechanism(s) and the potential
21 Future studies should evaluate whether resuscitation aimed at closin
22 Future studies should examine mechanisms that might explain differen
23 Future studies should examine the extent to which treatments aimed a
24 Future studies should examine whether treatment for MetS reduces the
25 Future studies should focus on potential mechanisms underlying these
26 Future studies should focus on strategies to reduce the placebo resp
27 Future studies should focus on the clinical value of full finger rep
28 Future studies should focus on the risk of injury progression.
29 Future studies should focus on the use of un-bias patient cohorts, d
30 Future studies should identify specific behaviors that mediate syphi
31 Future studies should include omics profiling to investigate sex-ass
32 Future studies should investigate the contamination and environmenta
33 Future studies should investigate whether CoVs detected in these bat
34 Future studies should investigate whether inflammatory pathways that
35 Future studies should investigate whether using measures of relative
36 Future studies should prospectively investigate these observed assoc
37 Future studies should seek to characterize WM abnormalities in young
38 Future studies should test higher doses of AV-101 in depression.
39 Future studies should use generalisable cohorts with longitudinal da
40 Future studies should use modern comprehensive batteries to better d
41 Future studies should use standard, clearly defined exposure variabl
42 ciated with dementia risk via multiple pathways, and
future studies should consider subtypes of depressive symptomatology
43 ionary significance of these underground structures,
future studies should consider these in combination with other bioti
44 in hepatic decompensation and mortality suggest that
future studies should focus on delivering evidence-based AUD treatme
45 We conclude that
future studies should test for other key environmental conditions, s
46 Third, post-
marketing studies should incorporate active comparators as appropriate.
47 Future prospective
multicenter studies should validate their role as a diagnostic biomarker.
48 demographics (age, gender, and ethnicity), and whether
such studies should not be performed using the same data that were
49 The results from
these studies should be evaluated with consideration to the diagnos
50 Transmission studies should consider the potential biases introduced by in